title: Add-on perampanel in Lance-Adams syndrome.
abstract: Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic-clonic seizures. A positive effect was reported in some patients with epileptic myoclonic jerks in idiopathic generalized epilepsy and in progressive myoclonic epilepsy. We treated a male patient with posthypoxic nonepileptic myoclonus (Lance-Adams syndrome) with add-on PER and achieved an almost complete cessation of jerks. This effect was reproducible and, therefore, we suggest that it might be worth trying PER in comparable cases.
authors.affiliation: Kork Epilepsy Center, Kehl-Kork, Germany.
authors.forename: Bernhard J
authors.initials: BJ
authors.lastname: Steinhoff
authors.affiliation: Kork Epilepsy Center, Kehl-Kork, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Bacher
authors.affiliation: Kork Epilepsy Center, Kehl-Kork, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Kurth
authors.affiliation: Kork Epilepsy Center, Kehl-Kork, Germany.
authors.forename: Anke M
authors.initials: AM
authors.lastname: Staack
authors.affiliation: Kork Epilepsy Center, Kehl-Kork, Germany.
authors.forename: Reinhold
authors.initials: R
authors.lastname: Kornmeier
keywords: Efficacy; Lance–Adams syndrome; Myoclonus; Perampanel